New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study estimates. But experts urge caution.

The FDA will decide on subcutaneous maintenance dosing of lecanemab by August. Some patients are opting for donanemab because that treatment has a set end date. Reaction from clinicians was varied, ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

Lilly is seeking approval for donanemab in early-stage Alzheimer's, and is hoping to get a speedy FDA green light on the back of amyloid clearance data as a surrogate marker for clinical efficacy ...

When you first enter a new world, you can either spawn near a structure or find one while exploring any of the three dimensions. While finding some can be quite easy, others are extremely hard to ...

Recently, lecanemab and donanemab have been shown to reduce the build-up in the brain of amyloid plaques -- a key characteristic of Alzheimer's disease -- and to slow down progression of the ...

A new £60,000-a-year Alzheimer's drug, said to be the first treatment to slow progression of the memory-robbing disease, is a rip off that results in 'tiny' benefits at the cost of deadly risks ...

Structural biology is the study of the molecular structure and dynamics of biological macromolecules, particularly proteins and nucleic acids, and how alterations in their structures affect their ...

In July 2024, the monoclonal antibody donanemab received Food and Drug Administration (FDA) approval as a treatment option for adults with early symptomatic Alzheimer’s disease, including people ...

Recently, lecanemab and donanemab have been shown to reduce the build-up in the brain of amyloid plaques – a key characteristic of Alzheimer's disease – and to slow down progression of the ...

They have long been left out of clinical trials, including recent trials of lecanemab and donanemab, the first drugs against Alzheimer’s that seem to slow the progress of the disease.